Retrophin Inc (NASDAQ:RTRX) has been assigned a consensus rating of “Hold” from the six research firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $44.00.
Several research firms have weighed in on RTRX. Zacks Investment Research cut Retrophin from a “hold” rating to a “sell” rating in a research report on Thursday. BidaskClub raised Retrophin from a “hold” rating to a “buy” rating in a research report on Wednesday. ValuEngine cut Retrophin from a “hold” rating to a “sell” rating in a research report on Monday, November 20th. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $44.00 price objective on shares of Retrophin in a research report on Friday, October 6th.
A number of institutional investors have recently bought and sold shares of RTRX. SG Americas Securities LLC boosted its position in Retrophin by 1.8% during the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 146 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Retrophin by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 355 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of Retrophin in the 3rd quarter worth approximately $203,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Retrophin in the 3rd quarter worth approximately $212,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Retrophin in the 3rd quarter worth approximately $249,000.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.21). The firm had revenue of $40.34 million for the quarter, compared to the consensus estimate of $40.51 million. Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. The business’s revenue was up 18.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.09) earnings per share. equities analysts forecast that Retrophin will post -1.25 EPS for the current year.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.